Access DB#

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Mike Miller Examiner #: 69404 Date: 5/27/03
Art Unit: 1654 Phone Number 30 8-4238 Serial Number: 10/088,525
Mail Box and Bldg/Room Location: CM1 10A03 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Remedios for intractable wound.

Inventors (please provide full names): Shoji Takakura, Kyoko Minawa

Earliest Priority Filing Date: 10/12/1999

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search the compound in claim 1.

RECEIVED
MAY 28 2003
CHEM, C...
(STIC)

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

****

STAFF USE ONLY

Searcher: Jan
Searcher Phone #: 4498
Searcher Location:
Date Searcher Picked Up: 5/29/03
Date Completed: 5/29/03
Searcher Prep & Review Time:
Clerical Prep Time: 10
Online Time:

PTO-1590 (8-01)

Type of Search

NA Sequence (#)
AA Sequence (#)
Structure (#) ✓
Bibliographic
Litigation
Fulltext
Patent Family
Other

Vendors and cost where applicable

STN
Dialog
Questel/Orbit
Dr.Link
Lexis/Nexis
Sequence Systems
WWW/Internet
Other (specify)

STIC Search Report
Biotech-Chem Library

USPTO

STIC Database Tracking Number: 95128

TO: Michael Meller **Location: 10A03** **Thursday, May 29, 2003** **Au: 1654** **Serial Number: 10 / 088525**	**From: Jan Delaval** **Location: Biotech-Chem Library** **CM1-1E07** **Phone: 308-4498** **jan.delaval@uspto.gov**

Search Notes

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

Search and Information Resources Administration

STIC SEARCH RESULTS

Biotech-Chem Library

Questions about the scope or the results of the search? Contact ***the searcher or contact:***

Mary Hale, Information Branch Supervisor
308-4258, CM1-1E01

Voluntary Results Feedback Form

- *I am an examiner in Workgroup:* ☐ *Example: 1610*
- *Relevant prior art **found**, search results used as follows:*
  - ☐ 102 rejection
  - ☐ 103 rejection
  - ☐ Cited as being of interest.
  - ☐ Helped examiner better understand the invention.
  - ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
  (journal articles, conference proceedings, new product announcements etc.)

- *Relevant prior art **not found:***
  - ☐ Results verified the lack of relevant prior art (helped determine patentability).
  - ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library CM1 – Circ. Desk

Jan Delaval
Reference Librarian
Biotechnology & Chemical Librar
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 06:38:34 ON 29 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 MAY 2003  HIGHEST RN 521913-14-4
DICTIONARY FILE UPDATES:  28 MAY 2003  HIGHEST RN 521913-14-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d ide can tot l7

L7   ANSWER 1 OF 4  REGISTRY  COPYRIGHT 2003 ACS
RN   144125-41-7  REGISTRY
CN   L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-
     [3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, (S)- (9CI)  (CA INDEX
     NAME)
FS   STEREOSEARCH
MF   C26 H33 F3 N4 O7
SR   CA
LC   STN Files:   CA, CAPLUS, USPATFULL

Absolute stereochemistry.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

              1 REFERENCES IN FILE CA (1957 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE   1:  117:212979

L7   ANSWER 2 OF 4  REGISTRY  COPYRIGHT 2003 ACS
RN   144125-40-6  REGISTRY
CN   L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-
     [3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, (R)- (9CI)  (CA INDEX
     NAME)
FS   STEREOSEARCH
```

MF **C26 H33 F3 N4 O7**
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 117:212979

L7 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2003 ACS
RN **144055-55-0** REGISTRY
CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, monosodium salt (9CI) (CA INDEX NAME)
OTHER NAMES:
CN FK 706
FS STEREOSEARCH
MF C26 H33 F3 N4 O7 . Na
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, DRUGNL, DRUGUPDATES, IPA, PHAR, TOXCENTER, USPATFULL
CRN (144055-51-6)

Absolute stereochemistry.



● Na

7 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:200832

REFERENCE 2: 137:103921

REFERENCE 3: 134:290425

REFERENCE 4: 132:245795

REFERENCE 5: 131:165341

REFERENCE 6: 127:341747

REFERENCE 7: 117:212979

L7 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2003 ACS
RN **144055-51-6** REGISTRY
CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C26 H33 F3 N4 O7**
CI COM
SR CA
LC STN Files: CA, CAPLUS, DRUGUPDATES, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 129:90460

REFERENCE 2: 117:212979

=> d his l7-

(FILE 'REGISTRY' ENTERED AT 06:27:33 ON 29 MAY 2003)
L7 4 S L2,L3,L5,L6

FILE 'HCAOLD' ENTERED AT 06:30:06 ON 29 MAY 2003
L8 0 S L7

FILE 'HCAPLUS' ENTERED AT 06:30:06 ON 29 MAY 2003
L9 8 S L7
L10 8 S FK706 OR FK 706
L11 12 S L9,L10
L12 1 S L11 AND (TAKAKURA ? OR MINOURA ?)/AU
L13 1 S L1 AND FUJISAWA?/PA,CS
L14 7 S L11 AND (PD<=20001002 OR PRD<=20001002 OR AD<=20001002)
L15 6 S L11 AND (PD<=19991002 OR PRD<=19991002 OR AD<=19991002)
L16 7 S L1,L12-L15

FILE 'USPATFULL, USPAT2' ENTERED AT 06:38:13 ON 29 MAY 2003
L17 3 S L11

FILE 'REGISTRY' ENTERED AT 06:38:34 ON 29 MAY 2003

=> fil uspatall
FILE 'USPATFULL' ENTERED AT 06:38:45 ON 29 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 06:38:45 ON 29 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> d l17 bib abs kwic hitstr tot

L17 ANSWER 1 OF 3 USPATFULL
AN 2002:251837 USPATFULL
TI Use of an LTB4 antagonist for the treatment or prevention of diseases caused by increased expression of mucin genes
IN Anderskewitz, Ralf, Laupheim, GERMANY, FEDERAL REPUBLIC OF
Meade, Christopher J. Montague, Bingen, GERMANY, FEDERAL REPUBLIC OF
Birke, Franz, Ingelheim, GERMANY, FEDERAL REPUBLIC OF
Jennewein, Hans Michael, Wiesbaden, GERMANY, FEDERAL REPUBLIC OF
Jung, Birgit, Schwabenheim, GERMANY, FEDERAL REPUBLIC OF
PI US 2002137792 A1 20020926
AI US 2002-50409 A1 20020116 (10)
PRAI GB 2001-1128 20010116
US 2001-266833P 20010206 (60)
DT Utility
FS APPLICATION
LREP BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 566
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Medicaments and pharmaceutical kits comprising an LTB.sub.4 antagonist of formula (I) ##STR1##

a tautomer thereof or a pharmaceutically acceptable salt thereof, and methods of treating or preventing cystic fibrosis, diseases caused by increased expression of mucin genes in the bronchial or gastrointestinal epithelium, or hyperplasia of goblet cells induced by toxins of products of pathogenic bacteria in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of an LTB.sub.4 antagonist of formula (I).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD . . . Such drugs include but are not confined to drugs which inhibit the production or action of neutrophil elastase such as **FK-706**, CE 1037, EPI-HNE-4, and alpha 1-antitrypsin.
CLM What is claimed is:
. . . to one of claims 1 to 6, wherein an additional active ingredient selected from the group consisting of atreleuton, zileuton, **FK-706**, CE 1037, EPI-HNE-4, alpha 1-antitrypsin, ambroxol, gentamycin, amikacin, kanamycin, streptomycin, neomycin, netimicin, colistin, iseganan, and tobramycinare, administered simultaneously or sequentially. . .
IT 57-92-1, Streptomycin, biological studies 1066-17-7, Colistin 1403-66-3, Gentamycin 1404-04-2, Neomycin 8063-07-8, Kanamycin 9041-92-3, .alpha.1-Antitrypsin 18683-91-5, Ambroxol 32986-56-4, Tobramycin 37517-28-5, Amikacin 56391-56-1, Netilmicin 111406-87-2, Zileuton **144055-55-0**, FK-706 150493-09-7, CE 1037

154355-76-7, Atreleuton 257277-05-7, Iseganan 346735-24-8
442911-16-2, DX 890
(LTB4 antagonist for treatment and/or prevention of diseases caused by increased expression of mucin genes)

IT **144055-55-0**, FK-706
(LTB4 antagonist for treatment and/or prevention of diseases caused by increased expression of mucin genes)

RN 144055-55-0 USPATFULL

CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 2 OF 3 USPATFULL

AN 2002:165223 USPATFULL

TI Method for treating respiratory disorders associated with pulmonary elastic fiber injury

IN Cantor, Jerome O., Brooklyn, NY, UNITED STATES
Kuo, Jing-wen, Wakefield, MA, UNITED STATES
Mihalko, Paul J., Fremont, CA, UNITED STATES
Sachs, Dan, Boston, MA, UNITED STATES
Turino, Gerard, New York, NY, UNITED STATES

PI US 2002086852 A1 20020704

AI US 2001-863849 A1 20010523 (9)

RLI Continuation-in-part of Ser. No. US 1998-79209, filed on 14 May 1998, PENDING

PRAI US 2000-206612P 20000523 (60)

DT Utility

FS APPLICATION

LREP BRYAN CAVE LLP, 245 Park Avenue, New York, NY, 10167

CLMN Number of Claims: 33

ECL Exemplary Claim: 1

DRWN 15 Drawing Page(s)

LN.CNT 2415

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to the field of respiratory therapeutics, and in particular to the treatment of disorders of the lung matrix caused by damage to the elastic fibers of the lung matrix. More specifically, methods and materials are disclosed for the delivery to the lungs of polysaccharides, derivatives thereof and/or drug conjugates, used in the treatment and/or prevention of pulmonary disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . elastase inhibitor: ABT-491 (Abbot)
HNE inhibitor: Ono-5046 (Ono)

Alpha 1-Antitrypsin:	Recombinant AT-1 (Novartis)
Elastase inhibitor:	Erdosteine (Edmond Pharma)
Elastase inhibitor:	**FK-706** (Fujisawa)
A1-AT agonist:	Gene Active AT-1 (Gene Medicine)
Elastase inhibitor:	Midesteine (Medea)
Proteinase inhibitor:	CMP-777 (Dupont)
HNE inhibitor:	CE-1037 (Cortech/United. . .

L17 ANSWER 3 OF 3 USPATFULL
AN 94:24423 USPATFULL
TI Trifluoromethylketone derivatives, processes for preparation thereof and use thereof
IN Hemmi, Keiji, Tsukuba, Japan
Shima, Ichiro, Ibaraki, Japan
Imai, Keisuke, Tsukuba, Japan
Tanaka, Hirokazu, Tsuchiura, Japan
PA Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)
PI US 5296591 19940322
AI US 1991-805610 19911212 (7)
PRAI GB 1990-28231 19901231
GB 1991-19713 19910916
DT Utility
FS Granted
EXNAM Primary Examiner: Moezie, F. T.
LREP Oblon, Spivak, McClelland, Maier & Neustadt
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1006
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The trifluoromethylketone derivatives (I) and pharmaceutically acceptable salts thereof have a human leukocyte elastase inhibiting activity and are useful as human leukocyte elastase inhibitors for treating or preventing degenerative diseases. The trifluoromethylketone derivatives (I) have the following formula: ##STR1## wherein R.sup.1 is C.sub.1-6 alkyl which has one or two substituents selected from carboxy, esterified carboxy and di-C.sub.1-6 alkylcarbamoyl; phenyl(C.sub.1-6) alkyl, the phenyl moiety of which may have halogen or nitro or amino substituents and the alkyl moiety of which may have carboxy or esterified carboxy substituents; halo-phenyl; morpholino; or morpholino(C.sub.1-6) alkyl,

R.sup.2 and R.sup.3 are each C.sub.1-6 alkyl,

X is -- or --NH--, and

Y is ##STR2## and pharmaceutically acceptable salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 144055-42-5P 144055-43-6P 144055-44-7P 144055-45-8P 144055-46-9P
144055-47-0P 144055-48-1P 144055-50-5P **144055-51-6P**
144055-52-7P 144055-53-8P 144055-54-9P **144055-55-0P**
144055-56-1P 144055-57-2P 144055-58-3P 144055-59-4P 144055-60-7P
144055-61-8P 144055-62-9P 144055-63-0P 144079-17-4P 144079-18-5P
144079-19-6P 144125-37-1P 144125-38-2P 144125-39-3P
144125-40-6P 144125-41-7P
(prepn. of, as human leukocyte elastase inhibitor)
IT **144055-51-6P 144055-55-0P 144125-40-6P**
144125-41-7P
(prepn. of, as human leukocyte elastase inhibitor)
RN 144055-51-6 USPATFULL
CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 144055-55-0 USPATFULL
CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 144125-40-6 USPATFULL
CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 144125-41-7 USPATFULL
CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 06:39:00 ON 29 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 29 May 2003 VOL 138 ISS 22
FILE LAST UPDATED: 28 May 2003 (20030528/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d all hitstr tot l16

L16 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:283813 HCAPLUS
DN 134:290425
TI Remedies for intractable wound
IN **Takakura, Shoji; Minoura, Kyoko**
PA **Fujisawa Pharmaceutical Co., Ltd., Japan**
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
IC ICM A61K045-00
ICS A61P017-02
CC 1-12 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001026685	A1	20010419	WO 2000-JP6873	20001002 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,

RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1230933 A1 20020814 EP 2000-963072 20001002 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL
BR 2000014831 A 20020827 BR 2000-14831 20001002 <--
PRAI JP 1999-289247 A 19991012 <--
WO 2000-JP6873 W 20001002 <--

AB These remedies contain as the active ingredient a substance having a human leukocyte elastase inhibitory activity. The effects of 3(RS)-[[4-(carboxymethylaminocarbonyl)-phenylcarbonyl]-L-valyl-L-prolyl]amino-1,1,1-trifluoro-4-methyl-2-oxopentane sodium salt (FR 136706) on the acetic acid-induced leg ulcer in normal and diabetic rats were examd.

ST wound healing leukocyte elastase inhibitor FR13670

IT Wound healing promoters
(human leukocyte elastase inhibitors as remedies for intractable wound)

IT Drug delivery systems
(topical; human leukocyte elastase inhibitors as remedies for intractable wound)

IT Skin, disease
(ulcer; human leukocyte elastase inhibitors as remedies for intractable wound)

IT **144055-55-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human leukocyte elastase inhibitors as remedies for intractable wound)

IT 9004-06-2, Elastase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(human leukocyte elastase inhibitors as remedies for intractable wound)

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Cortech Inc; EP 182906 A1 HCAPLUS
(2) Cortech Inc; WO 8600077 A1 1986 HCAPLUS
(3) Fujisawa Pharmaceutical Co Ltd; JP 04297446 A HCAPLUS
(4) Fujisawa Pharmaceutical Co Ltd; JP 06099378 B HCAPLUS
(5) Fujisawa Pharmaceutical Co Ltd; CN 1040003 B HCAPLUS
(6) Fujisawa Pharmaceutical Co Ltd; CN 1063108 A HCAPLUS
(7) Fujisawa Pharmaceutical Co Ltd; AT 151775 E HCAPLUS
(8) Fujisawa Pharmaceutical Co Ltd; CA 2058560 AA HCAPLUS
(9) Fujisawa Pharmaceutical Co Ltd; RU 2073684 C1 HCAPLUS
(10) Fujisawa Pharmaceutical Co Ltd; ES 2099755 T3 HCAPLUS
(11) Fujisawa Pharmaceutical Co Ltd; HU 210263 B HCAPLUS
(12) Fujisawa Pharmaceutical Co Ltd; EP 494071 A3 HCAPLUS
(13) Fujisawa Pharmaceutical Co Ltd; EP 494071 B1 HCAPLUS
(14) Fujisawa Pharmaceutical Co Ltd; US 5296591 A HCAPLUS
(15) Fujisawa Pharmaceutical Co Ltd; HU 60507 A2 HCAPLUS
(16) Fujisawa Pharmaceutical Co Ltd; AU 641577 B2 HCAPLUS
(17) Fujisawa Pharmaceutical Co Ltd; FI 9105996 A HCAPLUS
(18) Fujisawa Pharmaceutical Co Ltd; ZA 9110200 A HCAPLUS
(19) Fujisawa Pharmaceutical Co Ltd; AU 9189853 A1 HCAPLUS
(20) Fujisawa Pharmaceutical Co Ltd; NO 9200035 A HCAPLUS
(21) Fujisawa Pharmaceutical Co Ltd; EP 494071 A2 1992 HCAPLUS
(22) Heinzel-Wieland, R; BIOMEDICA BIOCHIMICA ACTA 1991, V50(4-6), P677 HCAPLUS

IT **144055-55-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human leukocyte elastase inhibitors as remedies for intractable wound)

RN 144055-55-0 HCAPLUS

CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

L16 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:804055 HCAPLUS
DN 132:245795
TI Smoking accelerates absorption of inhaled neutrophil elastase inhibitor **FK706**
AU Koizumi, Fumiaki; Murakami, Manabu; Kageyama, Hiromitsu; Katashima, Masataka; Terakawa, Masato; Ohnishi, Akihiro
CS Department of Internal Medicine, Jikei University School of Medicine, Daisan Hospital, Tokyo, 201-8601, Japan
SO Clinical Pharmacology & Therapeutics (St. Louis) (**1999**), 66(5), 501-508
CODEN: CLPTAT; ISSN: 0009-9236
PB Mosby, Inc.
DT Journal
LA English
CC 1-2 (Pharmacology)
Section cross-reference(s): 4
AB The pharmacokinetics of the inhaled neutrophil elastase inhibitor **FK706** were compared in healthy nonsmokers and smokers. The plasma concn.-time curves of inhaled **FK706** were different between smokers and nonsmokers. The max. plasma concns. (Cmax) were higher in the smokers than in the nonsmokers. The time to reach Cmax (tmax) and the elimination half-life (t1/2) were smaller in the smokers than in the nonsmokers. The area under the plasma concn.-time curve and plasma clearance were not significantly different between the 2 groups. Model-dependent pharmacokinetic anal., assuming a flip-flop model, revealed that the absorption rate const. (ka) was about 10-fold greater in smokers than in nonsmokers. Thus, significant increases of Cmax and ka and redns. of tmax and elimination t1/2 of the inhaled **FK706** were obsd. in the healthy smokers, suggesting that the smoking habit accelerates absorption of the after inhalation. Attention should be given to the drug-related adverse events caused by smoking, esp. when the drug has a narrow therapeutic range.
ST **FK 706** pharmacokinetics smoking; neutrophil elastase inhibitor **FK 706** pharmacokinetics smoking
IT Tobacco smoke
(smoking accelerates absorption of inhaled neutrophil elastase inhibitor **FK706** by humans)
IT 9004-06-2, Neutrophil elastase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; smoking accelerates absorption of inhaled neutrophil

elastase inhibitor **FK706** by humans)

IT **144055-55-0, FK 706**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(smoking accelerates absorption of inhaled neutrophil elastase inhibitor **FK706** by humans)

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Crane, J; Lancet 1989, V1, P917 MEDLINE
(2) Dawson, G; Pharmacol Ther 1982, V15, P207
(3) Elwood, R; Am Rev Respir Dis 1983, V128, P523 MEDLINE
(4) Gibaldi, M; Drugs and the pharmaceutical sciences 1975, V1, P35
(5) Groutas, W; Med Res Rev 1987, V7, P227 HCAPLUS
(6) Huchon, G; Am Rev Respir Dis 1984, V130, P457 MEDLINE
(7) Hunt, S; Clin Pharmacol Ther 1976, V19, P546 HCAPLUS
(8) Janoff, A; Am Rev Respir Dis 1985, V132, P417 MEDLINE
(9) Jones, D; Chest 1985, V88, P631 MEDLINE
(10) Jones, J; Lancet 1980, V1, P66 MEDLINE
(11) Jones, J; Thorax 1983, V38, P129 MEDLINE
(12) Kennedy, S; Am Rev Respir Dis 1984, V129, P143 MEDLINE
(13) Llewellyn-Jones, C; Am J Respir Crit Care Med 1996, V153, P616 MEDLINE
(14) MacNee, W; Am J Med 1991, V91(suppl 3C), P60S
(15) Mason, G; Chest 1985, V88, P327 MEDLINE
(16) McGuire, W; J Clin Invest 1982, V69, P543 HCAPLUS
(17) Minty, B; Br J Ind Med 1985, V42, P631 MEDLINE
(18) Minty, B; Br Med J (Clin Res Ed) 1981, V282, P1183 MEDLINE
(19) Neale, M; Br J Clin Pharmacol 1986, V22, P373 HCAPLUS
(20) Newhouse, M; Chest 1996, V110, P595 HCAPLUS
(21) O'Byrne, P; J Appl Physiol 1984, V57, P77 MEDLINE
(22) O'Connor, C; Am Rev Respir Dis 1993, V148, P1665 MEDLINE
(23) O'Doherty, M; Nucl Med Commun 1985, V6, P209 MEDLINE
(24) Pearce, N; Lancet 1995, V345, P41 MEDLINE
(25) Rinderknecht, J; Am Rev Respir Dis 1980, V121, P105 MEDLINE
(26) Schmekel, B; Thorax 1991, V46, P225 MEDLINE
(27) Taylor, G; Adv Drug Deliv Rev 1990, V5, P37 HCAPLUS
(28) Uchiba, M; Thromb Res 1995, V78, P117 HCAPLUS

IT **144055-55-0, FK 706**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(smoking accelerates absorption of inhaled neutrophil elastase inhibitor **FK706** by humans)

RN 144055-55-0 HCAPLUS

CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

L16 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:565936 HCAPLUS
DN 131:165341
TI Preventives/remedies for skin aging
IN Yabuta, Tsuguo; Yasumura, Mitsuru; Nakahara, Kunio; Furukawa, Yusuke; Nomura, Kazuhiko; Murakami, Manabu
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
IC ICM A61K045-00
ICS A61K038-03; C07K014-36; C07K005-093; C12P001-06
CC 1-12 (Pharmacology)
Section cross-reference(s): 62
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9943352	A1	19990902	WO 1999-JP761	19990219 <--
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1057491	A1	20001206	EP 1999-905256	19990219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
PRAI JP 1998-41479	A	19980224 <--		
WO 1999-JP761	W	19990219 <--		

OS MARPAT 131:165341
AB The invention relates to preventives/remedies for skin aging which contain as the active ingredient substances having an activity of inhibiting human leukocyte elastase [i.e. FR134043 and **FK706**].
ST skin aging leukocyte elastase inhibitor; antiaging FR134043 leukocyte elastase inhibitor; **FK706** antiaging leukocyte elastase inhibitor
IT Skin, disease
(aging; preventives/remedies for skin aging)
IT 9004-06-2, Elastase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human leukocyte, inhibitors for; preventives/remedies for skin aging)
IT **144055-55-0** 177079-46-8, FR 134043
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preventives/remedies for skin aging)
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Adir Et Co; FR 2694295 A HCAPLUS
(2) Adir Et Co; US 5565429 A HCAPLUS
(3) Adir Et Co; EP 585155 A HCAPLUS
(4) Adir Et Co; JP 06184192 A 1994 HCAPLUS
(5) Fujisawa Pharmaceutical Co Ltd; EP 465895 A HCAPLUS
(6) Fujisawa Pharmaceutical Co Ltd; EP 494071 A HCAPLUS
(7) Fujisawa Pharmaceutical Co Ltd; US 5292510 A HCAPLUS
(8) Fujisawa Pharmaceutical Co Ltd; US 5296591 A HCAPLUS
(9) Fujisawa Pharmaceutical Co Ltd; US 5364624 A HCAPLUS
(10) Fujisawa Pharmaceutical Co Ltd; JP 04279600 A 1992 HCAPLUS
(11) Fujisawa Pharmaceutical Co Ltd; JP 04297446 A 1992 HCAPLUS
IT **144055-55-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preventives/remedies for skin aging)

RN 144055-55-0 HCAPLUS
CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:479430 HCAPLUS
DN 129:90460
TI Remedies for cerebral ischemic diseases
IN Hisajima, Hiroshi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
IC ICM A61K038-55
ICS A61K045-00
CC 1-8 (Pharmacology)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827998	A1	19980702	WO 1997-JP4529	19971210 <--
	W: CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 2002161051	A2	20020604	JP 1996-343192	19961224 <--
PRAI	JP 1996-343192	A	19961224 <--		

OS MARPAT 129:90460
AB Disclosed are remedies for cerebral ischemic diseases, which contain substances having human leukocyte elastase inhibitory activities as the active ingredient. Particular examples of such substances include WS7622A mono- and disulfates, medicinally acceptable salts thereof, trifluoromethyl ketone derivs. such as 3(RS)-[[4-(carboxymethylaminocarbonyl)phenylcarbonyl]-L-valyl-L-prolyl]amino-1,1,1-trifluoro-4-methyl-2-oxopentane, and medicinally acceptable salts thereof.
ST cerebral ischemia elastase inhibitor WS7622A sulfate
IT Brain, disease
(ischemia; human leukocyte elastase inhibitors for treatment of cerebral ischemic diseases)
IT 140416-20-2 140416-21-3 140416-23-5 **144055-51-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human leukocyte elastase inhibitors for treatment of cerebral ischemic diseases)
IT 9004-06-2, Elastase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(human leukocyte elastase inhibitors for treatment of cerebral ischemic diseases)

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Cortex Pharmaceuticals Inc; JP 09500087 A 1994
(2) Cortex Pharmaceuticals Inc; EP 650368 A 1994
(3) Cortex Pharmaceuticals Inc; WO 9400095 A 1994 HCAPLUS
(4) Fujisawa Pharmaceutical Co Ltd; JP 03218387 A 1991 HCAPLUS
(5) Fujisawa Pharmaceutical Co Ltd; CA 2012074 A 1991 HCAPLUS
(6) Fujisawa Pharmaceutical Co Ltd; EP 387712 A 1991 HCAPLUS
(7) Fujisawa Pharmaceutical Co Ltd; US 5021240 A 1991 HCAPLUS
(8) Fujisawa Pharmaceutical Co Ltd; JP 04279600 A 1992 HCAPLUS
(9) Fujisawa Pharmaceutical Co Ltd; JP 04297446 A 1992 HCAPLUS
(10) Fujisawa Pharmaceutical Co Ltd; EP 465895 A 1992 HCAPLUS
(11) Fujisawa Pharmaceutical Co Ltd; EP 494071 A 1992 HCAPLUS
(12) Fujisawa Pharmaceutical Co Ltd; US 5292510 A 1992 HCAPLUS
(13) Fujisawa Pharmaceutical Co Ltd; US 5296591 A 1992 HCAPLUS
(14) Fujisawa Pharmaceutical Co Ltd; JP 05221872 A 1993 HCAPLUS
(15) Fujisawa Pharmaceutical Co Ltd; EP 519354 A 1993 HCAPLUS
(16) Fujisawa Pharmaceutical Co Ltd; US 5279826 A 1993 HCAPLUS
(17) Zeneca Ltd; JP 06508826 A 1994
(18) Zeneca Ltd; EP 589937 A 1994 HCAPLUS
(19) Zeneca Ltd; WO 9222309 A 1994 HCAPLUS

IT **144055-51-6**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human leukocyte elastase inhibitors for treatment of cerebral ischemic diseases)

RN 144055-51-6 HCAPLUS

CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2003 ACS

AN 1997:646588 HCAPLUS

DN 127:341747

TI Biochemical and pharmacological characterization of **FK706**, a novel elastase inhibitor

AU Shinguh, Yasuhiko; Imai, Keisuke; Yamazaki, Akiko; Inamura, Noriaki; Shima, Ichiro; Wakabayashi, Akiko; Higashi, Yasuyuki; Ono, Takaharu

CS Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 5-2-3 Tokodai, Tsukuba-shi, Ibaraki, 300-26, Japan

SO European Journal of Pharmacology (**1997**), 337(1), 63-71
CODEN: EJPHAZ; ISSN: 0014-2999

PB Elsevier

DT Journal

LA English

CC 1-12 (Pharmacology)

Section cross-reference(s): 14

AB **FK706**, sodium 2-[4-[[(S)-1-[[(S)-2-[[(RS)-3,3,3-trifluoro-1-isopropyl-2-oxopropyl]aminocarbonyl]pyrrolidin-1-yl]carbonyl]-2-methylpropyl]aminocarbonyl]benzoylamino]acetate (C26H32F3N4NaO7), is a synthetic water-sol. inhibitor of human neutrophil elastase. This compd. demonstrated a competitive and slow-binding inhibition of human neutrophil elastase with a Ki of 4.2 nM. In studies using synthetic substrates, **FK706** inhibited human neutrophil elastase activity and porcine pancreatic elastase activity with resp. IC50 values of 83 and 100 nM. **FK706**, however, inhibited more weakly, (IC50 values>340 .mu.M) other serine proteinases such as human pancreatic .alpha.-chymotrypsin, human pancreatic trypsin and human leukocyte cathepsin G. **FK706** also effectively inhibited the hydrolysis of bovine neck ligament elastin (2 mg/mL final concn.) by human neutrophil elastase (4 .mu.g/mL final concn.) with an IC50 value of 230 nM. **FK706** protected animals against human neutrophil elastase (50 .mu.g/animal)-induced lung hemorrhage with ED50 values of 2.4 .mu.g/animal by intratracheal administration and 36.5 mg/kg by i.v. administration, resp. S.c. administration of **FK706** significantly suppressed human neutrophil elastase (20 .mu.g/paw)-induced paw edema in mice in a dose-dependent manner (47% inhibition at a dose of 100 mg/kg). These results suggest that **FK706** would be a useful tool for investigating the role of human neutrophil elastase in inflammatory disorders assocd. with an excess of elastase, such as pulmonary emphysema, adult respiratory distress syndrome, septic shock, cystic fibrosis, chronic bronchitis and rheumatoid arthritis.

ST **FK706** elastase inhibitor biochem pharmacol

IT Edema
Emphysema
Hemorrhage
Neutrophil
(biochem. and pharmacol. characterization of novel human and lab. animal neutrophil elastase inhibitor **FK706** in relation to effect on hemorrhage and edema and pulmonary emphysema)

IT Enzyme kinetics
(of inhibition; biochem. and pharmacol. characterization of novel human and lab. animal neutrophil elastase inhibitor **FK706** in relation to effect on hemorrhage and edema and pulmonary emphysema)

IT **144055-55-0, FK 706**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(144055550; biochem. and pharmacol. characterization of novel human and lab. animal neutrophil elastase inhibitor **FK706** in relation to effect on hemorrhage and edema and pulmonary emphysema)

IT 9004-06-2, Elastase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(biochem. and pharmacol. characterization of novel human and lab. animal neutrophil elastase inhibitor **FK706** in relation to effect on hemorrhage and edema and pulmonary emphysema)

IT **144055-55-0, FK 706**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(144055550; biochem. and pharmacol. characterization of novel human and lab. animal neutrophil elastase inhibitor **FK706** in relation to effect on hemorrhage and edema and pulmonary emphysema)

RN 144055-55-0 HCAPLUS

CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

L16 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN 1997:559835 HCAPLUS
TI "Pharmacological evaluation of **FK706**, a novel and potent elastase inhibitor"
AU Yamazaki, Akiko; Shinguh, Yasuhiko; Inamura, Noriaki; Nakahara, Kunio; Shimomura, Kyouichi; Ono, Takaharu
SO Japanese Journal of Pharmacology (**1997**), 74(4), 341
CODEN: JJPAAZ; ISSN: 0021-5198
PB Japanese Pharmacological Society
DT Journal; Errata
LA English
AB Unavailable

L16 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN 1992:612979 HCAPLUS
DN 117:212979
TI Preparation of trifluoromethylketone tripeptide derivatives as human leukocyte elastase inhibitors
IN Hemmi, Keiji; Shima, Ichiro; Imai, Keisuke; Tanaka, Hirokazu
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C07K005-08
ICS A61K037-64
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI EP 494071	A2	19920708	EP 1992-100014	19920102	<--
EP 494071	A3	19930505			
EP 494071	B1	19970416			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE					
US 5296591	A	19940322	US 1991-805610	19911212	<--
FI 9105996	A	19920701	FI 1991-5996	19911219	<--
AU 9189853	A1	19920702	AU 1991-89853	19911219	<--
AU 641577	B2	19930923			
JP 04297446	A2	19921021	JP 1991-361134	19911219	<--
JP 06099378	B4	19941207			
RU 2073684	C1	19970220	RU 1991-5010583	19911228	<--
CA 2058560	AA	19920701	CA 1991-2058560	19911230	<--
CN 1063108	A	19920729	CN 1991-112615	19911230	<--
CN 1040003	B	19980930			
HU 60507	A2	19920928	HU 1991-4153	19911230	<--
HU 210263	B	19950328			

	ZA 9110200	A	19921028	ZA 1991-10200	19911230 <--
	NO 9200035	A	19920701	NO 1992-35	19920102 <--
	AT 151775	E	19970515	AT 1992-100014	19920102 <--
	ES 2099755	T3	19970601	ES 1992-100014	19920102 <--
PRAI	GB 1990-28231		19901231 <--		
	GB 1991-19713		19910916 <--		

OS MARPAT 117:212979

GI



I





II

AB Title compds. [I; R1 = alkyl[substituted by 1-2 of (esterified) carboxy, dialkylcarbanoyl, (substituted) phenylalkyl], halophenyl, morpholino, morpholinoalkyl; R2, R3 = alkyl; X = null, NH; Y = Q1, Q2], were prepd. Thus, II, prepd. via hydrogenolysis of the benzyl ester followed by salification, at 200 .mu.g/site intratracheally gave 97% inhibition of porcine pancreas elastase-induced emphysema in hamsters.

ST peptide trifluoromethyl ketone elastase inhibitor; drug peptidyltrifluoromethyl ketone

IT Transplant and Transplantation
(rejection of, treatment of, trifluoromethylketone tripeptide derivs. for)

IT Cystic fibrosis
Emphysema
Ischemia
Lupus erythematosus
Psoriasis
Sepsis and Septicemia
Shock
(treatment of, trifluoromethylketone tripeptide derivs. for)

IT Respiratory distress syndrome
(adult, treatment of, trifluoromethylketone tripeptide derivs. for)

IT Inflammation inhibitors
(antiarthritics, trifluoromethylketone tripeptide derivs.)

IT Bronchodilators
(antiasthmatics, trifluoromethylketone tripeptide derivs.)

IT Antiarteriosclerotics
(antiatherosclerotics, trifluoromethylketone tripeptide derivs.)

IT Lung, disease
(chronic obstructive, treatment of, trifluoromethylketone tripeptide derivs. for)

IT Respiratory tract
(disease, injury, treatment of, trifluoromethylketone tripeptide derivs. for)

IT Periodontium
(disease, periodontosis, treatment of, trifluoromethylketone tripeptide derivs. for)
IT Amnion
(disease, premature rupture, treatment of, trifluoromethylketone tripeptide derivs. for)
IT Bronchi
(diseases, bronchiectasis, treatment of, trifluoromethylketone tripeptide derivs. for)
IT Bronchi
(diseases, chronic bronchitis, treatment of, trifluoromethylketone tripeptide derivs. for)
IT Bronchi
(diseases, diffuse panbronchiolitis, treatment of, trifluoromethylketone tripeptide derivs. for)
IT Blood coagulation
(disorder, disseminated intravascular, treatment of, trifluoromethylketone tripeptide derivs. for)
IT Lung, disease
(fibrosis, treatment of, trifluoromethylketone tripeptide derivs. for)
IT Eye, disease
(keratoconjunctivitis, treatment of, trifluoromethylketone tripeptide derivs. for)
IT Kidney, disease
(nephritis, treatment of, trifluoromethylketone tripeptide derivs. for)
IT Pancreas, disease
(pancreatitis, treatment of, trifluoromethylketone tripeptide derivs. for)
IT Perfusion
(re-, treatment of, trifluoromethylketone tripeptide derivs. for)
IT Peptides, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(tri-, trifluoromethylketone derivs., prepn. of, as human leukocyte elastase inhibitors)
IT 109968-23-2, Elastase (human leukocyte protein moiety reduced)
RL: USES (Uses)
(inhibitors, trifluoromethylketone tripeptide derivs.)
IT 13734-41-3 16652-71-4, Proline benzyl ester hydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide coupling reaction of, in prepn. of human leukocyte elastase inhibitor)
IT 144055-42-5P 144055-43-6P 144055-44-7P 144055-45-8P 144055-46-9P
144055-47-0P 144055-48-1P 144055-50-5P **144055-51-6P**
144055-52-7P 144055-53-8P 144055-54-9P **144055-55-0P**
144055-56-1P 144055-57-2P 144055-58-3P 144055-59-4P 144055-60-7P
144055-61-8P 144055-62-9P 144055-63-0P 144079-17-4P 144079-18-5P
144079-19-6P 144125-37-1P 144125-38-2P 144125-39-3P
144125-40-6P 144125-41-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as human leukocyte elastase inhibitor)
IT 58872-03-0P 95501-60-3P 105080-02-2P 105095-20-3P 105095-21-4P
105181-51-9P 128483-86-3P 144055-64-1P 144055-65-2P 144055-66-3P
144055-67-4P 144055-68-5P 144055-69-6P 144055-70-9P 144055-71-0P
144055-72-1P 144055-73-2P 144055-74-3P 144055-75-4P 144055-76-5P
144079-20-9P 144079-21-0P 144079-22-1P 144125-42-8P 144125-43-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for human leukocyte elastase inhibitor)
IT 21760-98-5, Valine benzyl ester 144055-77-6 144055-78-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of human leukocyte elastase inhibitor)
IT 619-45-4, Methyl p-aminobenzoate 1679-64-7, Terephthalic acid monomethyl ester 1738-76-7, Glycine benzyl ester p-toluenesulfonate 2038-03-1, 4-(2-Aminoethyl)morpholine

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of peptide analog human leukocyte elastase inhibitor)

IT **144055-51-6P 144055-55-0P 144125-40-6P 144125-41-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as human leukocyte elastase inhibitor)

RN 144055-51-6 HCAPLUS
CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 144055-55-0 HCAPLUS
CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Na

RN 144125-40-6 HCAPLUS
CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 144125-41-7 HCAPLUS
CN L-Prolinamide, N-[4-[[(carboxymethyl)amino]carbonyl]benzoyl]-L-valyl-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil embase
FILE 'EMBASE' ENTERED AT 06:39:45 ON 29 MAY 2003

FILE COVERS 1974 TO 22 May 2003 (20030522/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot

L19 ANSWER 1 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 1999406523 EMBASE
TI Smoking accelerates absorption of inhaled neutrophil elastase inhibitor **FK706**.
AU Koizumi F.; Murakami M.; Kageyama H.; Katashima M.; Terakawa M.; Ohnishi A.
CS Dr. A. Ohnishi, Departments of Internal Medicine, Daisan Hospital, Jikei University School of Medicine, 4-11-1 Izumihoncho, Komae, Tokyo 201-8601, Japan
SO Clinical Pharmacology and Therapeutics, (1999) 66/5 (501-508).
Refs: 28
ISSN: 0009-9236 CODEN: CLPTAT
CY United States
DT Journal; Article
FS 030 Pharmacology
037 Drug Literature Index
LA English
SL English
AB Purpose: We compared the pharmacokinetics of the inhaled novel neutrophil elastase inhibitor **FK706** between healthy nonsmokers and smokers. Methods: Six healthy nonsmokers and six smokers inhaled 50 to 400 mg **FK706** in two different doses. Series of plasma concentrations of the SSS form of **FK706** (pharmacologically active epimer) were analyzed model dependently and independently. Pharmacokinetic parameters obtained from each group were compared after standardization by doses. Results: The plasma concentration- time curve of inhaled **FK706** was apparently different between smokers and nonsmokers. The maximum plasma concentrations (C(max)) were significantly higher in the smokers than in the nonsmokers (smokers, 1.47 .+-. 0.62 ng/mL/mg; nonsmokers, 0.49

.+-. 0.14 ng/mL/mg [mean .+-. SD; P < .01]). The time to reach C(max) (t(max)) and elimination half-life (t(1/2)) were statistically smaller in the smokers compared with the t(max) and elimination t(1/2) in the nonsmokers (t(max) in smokers, 0.44 .+-. 0.27 hours; t(max) in nonsmokers, 1.17 .+-. 0.39 hours [P < .01]; t(1/2) in smokers, 1.23 .+-. 0.40 hours; t(1/2) in nonsmokers, 2.73 .+-. 0.57 hours [P < .01]). The area under the plasma concentration-time curve and plasma clearance were not significantly different between the two groups. Model-dependent pharmacokinetic analysis, assuming a flip-flop model, revealed that the absorption rate constant (k(a)) was about 10 times greater in smokers than the k(a) in nonsmokers. Conclusion: Significant increases of C(max) and k(a) and reductions of t(max) and elimination t(1/2) of the inhaled **FK706** were observed in the healthy smokers, suggesting that the smoking habit accelerates the drug absorption after inhalation. These results suggest that we should pay attention to the drug-related adverse events caused by smoking, especially when the drug has a narrow therapeutic range.

CT Medical Descriptors:
*smoking
*drug absorption
drug blood level
drug half life
drug elimination
area under the curve
dose response
nebulizer
human
male
human experiment
normal human
adult
inhalational drug administration
article
priority journal
Drug Descriptors:
*leukocyte elastase inhibitor: DO, drug dose
*leukocyte elastase inhibitor: PK, pharmacokinetics
*2 [4 [[1 [[2 [(3,3,3 trifluoro 1 isopropyl 1 oxopropyl)aminocarbonyl]pyrrolidin 1 yl]carbonyl] 2 methylpropyl]aminocarbomyl]benzoylamino]acetate: DO, drug dose
*2 [4 [[1 [[2 [(3,3,3 trifluoro 1 isopropyl 1 oxopropyl)aminocarbonyl]pyrrolidin 1 yl]carbonyl] 2 methylpropyl]aminocarbomyl]benzoylamino]acetate: PK, pharmacokinetics
fk 706

CN **Fk 706**
NP (1) NE U07
CO (1) Omron (Japan)

L19 ANSWER 2 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 1999382736 EMBASE
TI Update on clinical trials in the treatment of pulmonary disease in patients with cystic fibrosis.
AU Shah P.L.
CS P.L. Shah, Royal Brompton Hospital, Sydney Street, London SW3 6NP, United Kingdom. pallav.shah@ic.ac.uk
SO Expert Opinion on Investigational Drugs, (1999) 8/11 (1917-1927).
Refs: 62
ISSN: 1354-3784 CODEN: EOIDER
CY United Kingdom
DT Journal; General Review
FS 015 Chest Diseases, Thoracic Surgery and Tuberculosis
030 Pharmacology
037 Drug Literature Index

LA English
SL English
AB Cystic fibrosis is a congenital disease resulting from an abnormality of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. A defect in ion transport leads to poor clearance of viscoelastic secretions and a susceptibility to bacterial infection. This initiates a self-perpetuating cycle of infection and inflammation that accounts for the chronic endobronchial sepsis and pulmonary damage observed in patients with cystic fibrosis. Recent studies have attempted to correct the gene defect, enhance the expression and function of the CFTR protein and correct the ion transport defect. Improving the rheological properties of airway secretions, enhancing host defence and controlling inflammation are the other key strategies.
CT Medical Descriptors:
*lung disease: CO, complication
*lung disease: DT, drug therapy
*cystic fibrosis: CN, congenital disorder
*cystic fibrosis: TH, therapy
ion transport
infection sensitivity
protein expression
secretions
host resistance
gene therapy
human
review
Drug Descriptors:
transmembrane conductance regulator: EC, endogenous compound
antiinflammatory agent: DT, drug therapy
proteinase inhibitor: DT, drug therapy
arylbutyric acid derivative: DT, drug therapy
arylbutyric acid derivative: PD, pharmacology
8 cyclopentyl 1,3 dipropylxanthine: DT, drug therapy
8 cyclopentyl 1,3 dipropylxanthine: PD, pharmacology
amiloride: DT, drug therapy
sodium channel blocking agent: DT, drug therapy
dornase alfa: DT, drug therapy
gelsolin: DT, drug therapy
nacystelyn: DT, drug therapy
tyloxapol: DT, drug therapy
lung surfactant: DT, drug therapy
mannitol: DT, drug therapy
dextran: DT, drug therapy
tobramycin: DO, drug dose
tobramycin: DT, drug therapy
pseudostat: DT, drug therapy
pseudomonas antibody: DT, drug therapy
rbpi 21: DT, drug therapy
pentoxifylline: DT, drug therapy
alpha 1 antitrypsin: DT, drug therapy
secretory leukocyte proteinase inhibitor: DT, drug therapy
ce 1037: DT, drug therapy
n [1 (1,3 benzodioxol 5 yl)butyl] 3,3 diethyl 2 [4 [(4 methyl 1 piperazinyl)carbonyl]phenoxy] 4 oxo 1 azetidinecarboxamide: DT, drug therapy
fk 706: DT, drug therapy
RN (proteinase inhibitor) 37205-61-1; (8 cyclopentyl 1,3 dipropylxanthine) 102146-07-6; (amiloride) 2016-88-8, 2609-46-3; (dornase alfa) 143831-71-4; (tyloxapol) 25301-02-4; (lung surfactant) 99732-49-7; (mannitol) 69-65-8, 87-78-5; (dextran) 87915-38-6, 9014-78-2; (tobramycin) 32986-56-4; (pentoxifylline) 6493-05-6; (alpha 1 antitrypsin) 9041-92-3; (n [1 (1,3 benzodioxol 5 yl)butyl] 3,3 diethyl 2 [4 [(4 methyl 1 piperazinyl)carbonyl]phenoxy] 4 oxo 1 azetidinecarboxamide) 157341-41-8

CN (1) Exosurf; (2) Ce 1037; (3) Dmp 777; **(4) Fk 706**
CO (1) Glaxo; (2) Cortech; (3) Du Pont; (4) Fujisawa; SMB; Discovery; Hoffmann La Roche; Tobishi Pharmaceutical; Tobi; Genentech; Biogen; Univax; Genzyme; Hoechst Marion Roussel; Ppl therapeutics; Synergen; Amgen; Cortecs; Xoma; Sciclone

L19 ANSWER 3 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 1999161588 EMBASE
TI The protease-antiprotease battle in the cystic fibrosis lung.
AU Balfour-Lynn I.M.
CS I.M. Balfour-Lynn, Dept. Paediat. Respiratory Medicine, Royal Brompton Harefield NHS Trust, Sydney Street, London SW3 6NP, United Kingdom
SO Journal of the Royal Society of Medicine, Supplement, (1999) 92/37 (23-30).
Refs: 65
ISSN: 0267-5331 CODEN: JRMSEW
CY United Kingdom
DT Journal; Conference Article
FS 004 Microbiology
006 Internal Medicine
007 Pediatrics and Pediatric Surgery
015 Chest Diseases, Thoracic Surgery and Tuberculosis
026 Immunology, Serology and Transplantation
037 Drug Literature Index
038 Adverse Reactions TitlesAdverse Reactions Titles
LA English
CT Medical Descriptors:
*cystic fibrosis: CN, congenital disorder
*cystic fibrosis: DT, drug therapy
*cystic fibrosis: ET, etiology
pneumonia: DT, drug therapy
pneumonia: ET, etiology
respiratory tract infection: ET, etiology
pseudomonas aeruginosa
recurrent infection: ET, etiology
neutrophil
respiratory epithelium
thorax disease: SI, side effect
arthralgia: SI, side effect
respiratory tract disease: SI, side effect
nebulizer
drug tolerability
transgene
gene therapy
human
oral drug administration
inhalational drug administration
conference paper
Drug Descriptors:
*proteinase: EC, endogenous compound
*proteinase inhibitor: AE, adverse drug reaction
*proteinase inhibitor: AD, drug administration
*proteinase inhibitor: CR, drug concentration
*proteinase inhibitor: DO, drug dose
*proteinase inhibitor: DT, drug therapy
*proteinase inhibitor: EC, endogenous compound
*proteinase inhibitor: PK, pharmacokinetics
*proteinase inhibitor: PD, pharmacology
transmembrane conductance regulator: EC, endogenous compound
cytokine: EC, endogenous compound
bacterial enzyme
leukocyte elastase
alpha 1 antitrypsin: AE, adverse drug reaction

alpha 1 antitrypsin: AD, drug administration
alpha 1 antitrypsin: CR, drug concentration
alpha 1 antitrypsin: DO, drug dose
alpha 1 antitrypsin: DT, drug therapy
alpha 1 antitrypsin: EC, endogenous compound
alpha 1 antitrypsin: PK, pharmacokinetics
alpha 1 antitrypsin: PD, pharmacology
secretory leukocyte proteinase inhibitor: DO, drug dose
secretory leukocyte proteinase inhibitor: DT, drug therapy
secretory leukocyte proteinase inhibitor: EC, endogenous compound
secretory leukocyte proteinase inhibitor: PK, pharmacokinetics
secretory leukocyte proteinase inhibitor: PD, pharmacology
n [1 (1,3 benzodioxol 5 yl)butyl] 3,3 diethyl 2 [4 [(4 methyl 1 piperazinyl)carbonyl]phenoxy] 4 oxo 1 azetidinecarboxamide: AD, drug administration
n [1 (1,3 benzodioxol 5 yl)butyl] 3,3 diethyl 2 [4 [(4 methyl 1 piperazinyl)carbonyl]phenoxy] 4 oxo 1 azetidinecarboxamide: DV, drug development
n [1 (1,3 benzodioxol 5 yl)butyl] 3,3 diethyl 2 [4 [(4 methyl 1 piperazinyl)carbonyl]phenoxy] 4 oxo 1 azetidinecarboxamide: PD, pharmacology
3 acetoxymethyl 2 (2 carboxy 1 pyrrolidinylcarbonyl) 7alpha methoxy 8 oxo 5 thia 1 azabicyclo[4.2.0]oct 2 ene 5,5 dioxide: AD, drug administration
3 acetoxymethyl 2 (2 carboxy 1 pyrrolidinylcarbonyl) 7alpha methoxy 8 oxo 5 thia 1 azabicyclo[4.2.0]oct 2 ene 5,5 dioxide: DV, drug development
3 acetoxymethyl 2 (2 carboxy 1 pyrrolidinylcarbonyl) 7alpha methoxy 8 oxo 5 thia 1 azabicyclo[4.2.0]oct 2 ene 5,5 dioxide: PD, pharmacology
[4 (4 bromophenylsulfonylcarbamoyl)benzoyl]valylproline n (2 methyl 1 trifluoroacetylpropyl)amide: AD, drug administration
[4 (4 bromophenylsulfonylcarbamoyl)benzoyl]valylproline n (2 methyl 1 trifluoroacetylpropyl)amide: DV, drug development
[4 (4 bromophenylsulfonylcarbamoyl)benzoyl]valylproline n (2 methyl 1 trifluoroacetylpropyl)amide: PD, pharmacology
fk 706: AD, drug administration
fk 706: DV, drug development
fk 706: PD, pharmacology

RN (proteinase) 9001-92-7; (proteinase inhibitor) 37205-61-1; (leukocyte elastase) 109968-22-1; (alpha 1 antitrypsin) 9041-92-3; (n [1 (1,3 benzodioxol 5 yl)butyl] 3,3 diethyl 2 [4 [(4 methyl 1 piperazinyl)carbonyl]phenoxy] 4 oxo 1 azetidinecarboxamide) 157341-41-8; (3 acetoxymethyl 2 (2 carboxy 1 pyrrolidinylcarbonyl) 7alpha methoxy 8 oxo 5 thia 1 azabicyclo[4.2.0]oct 2 ene 5,5 dioxide) 116507-04-1; ([4 (4 bromophenylsulfonylcarbamoyl)benzoyl]valylproline n (2 methyl 1 trifluoroacetylpropyl)amide) 105080-32-8
CN (1) Prolastin
CO (1) Bayer (United States)

L19 ANSWER 4 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 97337695 EMBASE
DN 1997337695
TI Biochemical and pharmacological characterization of **FK706**, a novel elastase inhibitor.
AU Shinguh Y.; Imai K.; Yamazaki A.; Inamura N.; Shima I.; Wakabayashi A.; Higashi Y.; Ono T.
CS Y. Shinguh, Exploratory Research Laboratories, Fujisawa Pharmaceutical Co. Ltd, 5-2-3 Tokodai, Tsukuba-shi, Ibaraki 300-26, Japan
SO European Journal of Pharmacology, (1997) 337/1 (63-71).
Refs: 38
ISSN: 0014-2999 CODEN: EJPHAZ
PUI S 0014-2999(97)01284-3
CY Netherlands
DT Journal; Article
FS 029 Clinical Biochemistry

030 Pharmacology
037 Drug Literature Index
LA English
SL English
AB **FK706**, sodium 2-[4-[[(S)-1-[[(S)-2-[[(RS)-3, 3, 3 -trifluoro-1-isopropyl-2-oxopropyl]aminocarbonyl]pyrrolidin-1-yl]carbonyl]-2 -methylpropyl] aminocarbonyl] benzoylamino] acetate, C26H32F3N4NaO7, is a synthetic water-soluble inhibitor of human neutrophil elastase. This compound demonstrated a competitive and slow-binding inhibition of human neutrophil elastase with a K(i) of 4.2 nM. In studies using synthetic substrates, **FK706** inhibited human neutrophil elastase activity and porcine pancreatic elastase activity with respective values of 83 and 100 nM. **FK706**, however, inhibited more weakly, (IC50 values > 340 .mu.M) other serine proteinases such as human pancreatic .alpha.-chymotrypsin, human pancreatic trypsin and human leukocyte cathepsin G. **FK706** also effectively inhibited the hydrolysis of bovine neck ligament elastin (2 mg/ml final concentration) by human neutrophil elastase (4 .mu.g/ml final concentration) with an IC50 value of 230 nM. **FK706** protected animals against human neutrophil elastase (50 .mu.g/animal)-induced lung hemorrhage with ED50 values of 2.4 .mu.g/animal by intratracheal administration and 36.5 mg/kg by intravenous administration, respectively. Subcutaneous administration of **FK706** significantly suppressed human neutrophil elastase (20 .mu.g/paw)-induced paw edema in mice in a dose-dependent manner (47% inhibition at a dose of 100 mg/kg). These results suggest that **FK706** would be a useful tool for investigating the role of human neutrophil elastase in inflammatory disorders associated with an excess of elastase, such as pulmonary emphysema, adult respiratory distress syndrome, septic shack, cystic fibrosis, chronic bronchitis and rheumatoid arthritis.
CT Medical Descriptors:
*connective tissue disease: ET, etiology
*enzyme inhibition
adult respiratory distress syndrome: ET, etiology
animal experiment
animal model
animal tissue
article
chronic bronchitis: ET, etiology
controlled study
cystic fibrosis: ET, etiology
hamster
human
human cell
lung emphysema: ET, etiology
mouse
nonhuman
priority journal
rheumatoid arthritis: ET, etiology
Drug Descriptors:
*elastase inhibitor: PD, pharmacology
***fk 706: PD, pharmacology**
leukocyte elastase: EC, endogenous compound
unclassified drug
RN (leukocyte elastase) 109968-22-1
CN **Fk 706**

L19 ANSWER 5 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 97288827 EMBASE
DN 1997288827
TI Erratum: O-292 'Pharmacological evaluation of **FK706**, a novel and potent elastase inhibitor' (The Japanese Journal of Pharamacology (1997) 74 (114)).
AU Yamazaki A.; Shinguh Y.; Inamura N.; Nakahara K.; Shimomura K.; Ono T.

SO Japanese Journal of Pharmacology, (1997) 74/4 (341).
Refs: 0
ISSN: 0021-5198 CODEN: JJPAAZ
CY Japan
DT Journal; Errata
FS 030 Pharmacology
LA English
CT Medical Descriptors:
*error
erratum

=> fil biosis
FILE 'BIOSIS' ENTERED AT 06:40:35 ON 29 MAY 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 28 May 2003 (20030528/ED)

=> d all

L22 ANSWER 1 OF 1 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 1997:235804 BIOSIS
DN PREV199799535007
TI Pharmacological evaluation of **FK706**, a novel and potent elastase inhibitor.
AU Yamazaki, Akiko; Shinguh, Yasuhiko; Inamura, Noriaki; Nakahara, Kunio; Shimomura, Kyouichi; Ono, Takaharu
CS Exploratory Res. Lab., Fujisawa Pharmaceutical Co. Ltd., 5-2-3 Tokodai, Tsukuba 300-26 Japan
SO Japanese Journal of Pharmacology, (1997) Vol. 73, No. SUPPL. 1, pp. 114P.
Meeting Info.: 70th Annual Meeting of the Japanese Pharmacological Society Chiba, Japan March 22-25, 1997
ISSN: 0021-5198.
DT **Conference**; Abstract
LA English
CC General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520
Cytology and Cytochemistry - Human *02508
Enzymes - General and Comparative Studies; Coenzymes *10802
Respiratory System - General; Methods *16001
Pharmacology - General *22002
Immunology and Immunochemistry - General; Methods *34502
BC Suidae 85740
Hominidae 86215
Cricetidae 86310
Muridae *86375
IT Major Concepts
Cell Biology; Enzymology (Biochemistry and Molecular Biophysics); Immune System (Chemical Coordination and Homeostasis); Pharmacology; Respiratory System (Respiration)
IT Chemicals & Biochemicals
ELASTASE
IT Miscellaneous Descriptors
BLOOD AND LYMPHATICS; DIGESTIVE SYSTEM; ELASTASE; ELASTASE INHIBITOR; ENDOCRINE SYSTEM; ENZYME INHIBITOR-DRUG; **FK706**; IMMUNE SYSTEM; LUNG HEMORRHAGE; NEUTROPHIL; PANCREAS; PHARMACOLOGICAL EVALUATION; PHARMACOLOGY; PULMONARY EMPHYSEMA; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY SYSTEM DISEASE; VASCULAR DISEASE

```
ORGN Super Taxa
        Cricetidae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia;
        Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia; Muridae:
        Rodentia, Mammalia, Vertebrata, Chordata, Animalia; Suidae:
        Artiodactyla, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
        hamster (Cricetidae); human (Hominidae); mouse (Muridae); pig (Suidae)
ORGN Organism Superterms
        animals; artiodactyls; chordates; humans; mammals; nonhuman mammals;
        nonhuman vertebrates; primates; rodents; vertebrates
RN   9004-06-2 (ELASTASE)


=> d his

     (FILE 'HOME' ENTERED AT 06:26:50 ON 29 MAY 2003)
                SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 06:27:20 ON 29 MAY 2003
                E WO2000-JP6873/AP,PRN
L1             1 S E3,E4

     FILE 'REGISTRY' ENTERED AT 06:27:33 ON 29 MAY 2003
L2             1 S 144055-55-0
L3             1 S 144055-51-6
                 E C26H33F3N4O7/MF
L4             5 S E3 AND NC4/ES AND 46.150.18/RID
L5             3 S L4 NOT ALANYL
                 SEL RN
L6             1 S E1-E3/CRN
L7             4 S L2,L3,L5,L6

     FILE 'HCAOLD' ENTERED AT 06:30:06 ON 29 MAY 2003
L8             0 S L7

     FILE 'HCAPLUS' ENTERED AT 06:30:06 ON 29 MAY 2003
L9             8 S L7
L10            8 S FK706 OR FK 706
L11           12 S L9,L10
L12            1 S L11 AND (TAKAKURA ? OR MINOURA ?)/AU
L13            1 S L1 AND FUJISAWA?/PA,CS
L14            7 S L11 AND (PD<=20001002 OR PRD<=20001002 OR AD<=20001002)
L15            6 S L11 AND (PD<=19991002 OR PRD<=19991002 OR AD<=19991002)
L16            7 S L1,L12-L15

     FILE 'USPATFULL, USPAT2' ENTERED AT 06:38:13 ON 29 MAY 2003
L17            3 S L11

     FILE 'REGISTRY' ENTERED AT 06:38:34 ON 29 MAY 2003

     FILE 'USPATFULL, USPAT2' ENTERED AT 06:38:45 ON 29 MAY 2003

     FILE 'HCAPLUS' ENTERED AT 06:39:00 ON 29 MAY 2003

     FILE 'EMBASE' ENTERED AT 06:39:18 ON 29 MAY 2003
L18            9 S L11
L19            5 S L18 AND PY<=2000

     FILE 'EMBASE' ENTERED AT 06:39:45 ON 29 MAY 2003

     FILE 'BIOSIS' ENTERED AT 06:39:55 ON 29 MAY 2003
L20            4 S L11
L21            3 S L20 AND PY<=2000
```

L22 1 S L21 AND CONFERENCE/DT

FILE 'BIOSIS' ENTERED AT 06:40:35 ON 29 MAY 2003